Latest Safety News

Orthocell Limited reports an 81.1% overall treatment success rate from its Remplir Real World Evidence study, reinforcing the product’s safety and efficacy as it expands sales in the US and prepares regulatory submissions for the EU and UK.

Finder Energy is fast-tracking its Kuda Tasi and Jahal development with advanced engineering and critical FPSO evaluations, aiming for a Final Investment Decision in 2026. This acceleration seeks to reduce risks and optimize costs ahead of production.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

PYC Therapeutics has completed dosing in its Phase 1 study of PYC-001 for Autosomal Dominant Optic Atrophy, showing strong safety and early signs of improved vision. The company plans to launch a global Phase 1/2 trial later this year.

Botanix Pharmaceuticals’ ECCLOCK® gel, a treatment for excessive sweating, has secured regulatory approval in South Korea, paving the way for a commercial launch in early 2026.

Orica Limited reports robust earnings growth across all segments for FY2025, underpinned by successful gas supply deals, digital expansion, and progress in hydrogen funding despite ongoing litigation costs.

Haranga Resources has successfully commissioned the water treatment plant at its Lincoln Gold Project and begun dewatering, paving the way for its maiden underground drilling program and a JORC resource update by year-end.

Amplia Therapeutics has commenced dosing the first patient in its new pancreatic cancer trial combining narmafotinib with FOLFIRINOX chemotherapy, marking a key milestone in its drug development journey.

Argenica Therapeutics has reported positive Phase 2 trial results for ARG-007 in acute ischemic stroke patients, confirming safety and revealing a promising efficacy signal in a high-risk subgroup with slow collateral blood flow.

Brazilian Rare Earths Limited has obtained the final regulatory approval to operate its rare earth pilot plant in Brazil’s largest petrochemical complex, setting the stage for pilot operations in mid-2026.

4DMedical has won a crucial US Medicare reimbursement for its CT, VQ™ lung imaging software, paving the way for rapid adoption across American hospitals. This milestone follows FDA clearance and promises to transform lung diagnostics with safer, faster scans.

Intelligent Monitoring Group has completed its $4.5 million acquisition of Western Advance, bolstering its presence in Western Australia's oil and gas security sector.